Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency)
Net loss of $6.7 million – an improvement of $6.5 million year over year
Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results.
“Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “As we shared at our recent Analyst and Investor Day, we will continue to drive growth with our market-leading products through robust innovation, clinical evidence generation, and therapy awareness to benefit more providers and patients, while expanding profitability.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.